International digital therapeutics leader Sidekick Health announced that it has raised $55 million in Series B funding. The round was led by London-based venture capital firm Novator Ventures, with additional participation from Asabys Partners, Wellington Partners and Frumtak Ventures, as well as a US-based strategic investor that will be revealed at a later stage. In 2020 the company raised a $20 million Series A led by Wellington Partners and Asabys Partners.
Sidekick is on amission to develop and deliver effective, personalized digital therapeutics that prevent suffering and add millions of quality life years to people around the world. Digital therapeutics are the next generation of therapeutics designed to prevent, treat and help people manage a wide range of medical disorders or diseases.
“Sidekick clearly reflects the vision we have at Asabys about the possibility of creating scientific evidence-based digital therapies that have a real impact on patients' health, in a manner analogous to traditional pharmacological treatment. Sidekick is also proving to be able to generate value for key healthcare stakeholders, including large pharmaceutical and insurance companies, who are willing to enter into long-term business agreements with Sidekick in order to use this technology. With this round, the company will have the resources to be able to continue crashing at high speed ", comment Clara Campàs and Guillem Masferrer of Asabys.
Photo: Sidekick co-founders, Sam Oddsson and Tryggvi Thorgeirsson.
Comments